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Abstract
Background: The majority of colorectal cancer (CRC) cases develop through the adenoma-
carcinoma pathway. If an increase in DNA repair expression is detected in both early adenomas
and carcinomas it may indicate that low repair capacity in the normal mucosa is a risk factor for
adenoma formation.
Methods: We have examined mRNA expression of two DNA repair genes, ERCC1 and OGG1 as
well as the putative apoptosis controlling gene RAI, in normal tissues and lesions from 36 cases with
adenomas (mild/moderat n = 21 and severe n = 15, dysplasia) and 9 with carcinomas.
Results: Comparing expression levels of ERCC1, OGG1 and RAI between normal tissue and all
lesions combined yielded higher expression levels in lesions, 3.3-fold higher (P = 0.005), 5.6-fold
higher(P < 3·10-5) and 7.7-fold higher (P = 0.0005), respectively. The levels of ERCC1, OGG1 and RAI
expressions when comparing lesions, did not differ between adenomas and CRC cases, P = 0.836,
P = 0.341 and P = 0.909, respectively. When comparing expression levels in normal tissue, the
levels for OGG1 and RAI from CRC cases were significantly lower compared to the cases with
adenomas, P = 0.012 and P = 0.011, respectively.
Conclusion: Our results suggest that increased expression of defense genes is an early event in
the progression of colorectal adenomas to carcinomas.
Background
Most colorectal cancers (CRC) develop through multiple
mutations in the normal colonic mucosa, and evolve
through the adenoma-carcinoma sequence [1,2]. Various
endogenous and exogenous agents from environmental
exposures are constantly damaging DNA, and in combi-
nation with low DNA repair capacity this have been inter-
preted as increasing the likelihood of cancer development
[3-7].
The range of different DNA lesions is broad and there are
different repair pathways depending on the nature of the
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damage. Nucleotide excision repair (NER) will repair
bulky adducts [8] while base excision repair (BER) is
responsible for the repair of base damage and single
strand breaks [9]. Only a few studies have to our knowl-
edge studied DNA repair expression of nucleotide excision
repair (NER) and base excision repair (BER) genes in CRC.
Even less is known about the level and significance of
DNA repair expression during the formation of adenomas
and the transition period in the adenoma-carcinoma
sequence. Previous studies have indicated that the NER
gene excision repair cross-complementation group1
(ERCC1) and BER gene 8-oxoguanine glycosylase 1
(OGG1) may be inducible [10] and they have also been
shown to correlate with enhanced DNA repair activities
[11-15]. DNA repair mechanisms are complex and
involve several genes. OGG1 and ERCC1 are among the
few for which it has been shown that mRNA levels and
repair activity correlate. The ERCC1 gene encodes a subu-
nit of the nucleotide excision repair complex required for
the incision step of NER [16,17]. Several factors indicate
that the ERCC1 mRNA levels can be used as a proxy for
DNA repair capacity. The mRNA levels of ERCC1 may cor-
relate with DNA repair capacity in various tissues [11-
13,15], and also predict the response to chemotherapy
(high  ERCC1  levels have been associated with tumor
growth and lower levels have been associated with
improved disease response) [15,18-21]. In addition, inter-
individual variation of ERCC1 mRNA levels is much larger
than the intra-individual variation [22], indicating that
the mRNA level of ERCC1 may be used as a biomarker for
NER.
The enzymes responsible for the BER process which repair
damaged bases, abasic sites and single-strand breaks are
initiated by specific DNA glycosylases. The DNA glycosy-
lase OGG1 removes 8-oxo-guanine (8-oxoG) directly
from damaged DNA [23,24]. Kondo et al concluded that
there is a correlation between 8-OHdG levels and hOGG1
expression in CRC tissue [14]. Kondo et al also concluded
that colorectal carcinoma cells but not adenoma cells are
exposed to more oxidative stress than corresponding nor-
mal tissue [25]. Previous studies have shown that oxida-
tive stress is generally proportional to OGG1  mRNA
expression and activity [10,26,27]. To the best of our
knowledge, it has not been investigated if increased OGG1
expression is an early or late event in the adenoma-carci-
noma sequence. It is therefore of interest to study and
compare the expression of OGG1 in adenoma and carci-
noma tissues.
There are several responses to DNA damage including
induction of apoptose to eliminate damaged cells. The
putative apoptosis controlling gene RAI was included to
determine if the expression of RAI was coordinated with
the expression of ERCC1. Both genes are located on chro-
mosome 19q13.2. The RelA associated inhibitor (RAI)
gene, encodes an inhibitor of the RelA subunit of the tran-
scription factor NF-κB [28]. The inclusion of this gene is
more explorative but previous studies suggest that RAI is
involved in carcinogenesis [29]. High levels of RAI seem
to promote apoptosis while low levels of RAI may inhibit
apoptosis, although the literature is not clear on this issue
[28,30]. This is to the best of our knowledge the first study
to investigate if increased RAI expression is an early or late
event in the adenoma-carcinoma sequence.
In this study we have measured mRNA levels of ERCC1,
OGG1 and RAI in patients with colorectal adenomas and
carcinomas (normal colonic mucosa and lesions).
The main focus was to investigate if increased expression
of DNA repair genes is an early or late event in the ade-
noma-carcinoma sequence. By studying repair genes in
the various stages of the adenoma-carcinoma sequence,
we may gain new information on the significance of repair
capacity in normal and neoplastic tissues during transi-
tion.
Methods
The KAM biobank (Kolorektal cancer, Arv og Miljø) is
based on the screening group of the Norwegian Colorectal
Cancer Prevention study (The NORCCAP study) in the
county of Telemark [31]. The ID number for the NORC-
CAP study at clinicaltrials.gov is I NCT00119912 [32]. The
KAM biobank has previously been described by Hansen et
al. [33]. In the present study we have selected and ana-
lyzed cases with adenocarcinomas (9) and cases with ade-
nomas (36). The sampling pool of cases contains tissue
(normal colonic mucosa and lesion) from 180 CRC cases
and 242 adenoma cases. The cases are matched for age
and gender. The adenocarcinomas were collected prior to
chemo- or radiotherapy treatment. The tumor histology of
the adenomas was examined independently by two spe-
cialist histopathologists in order to determine the tumor
stage as either mild/moderate (n = 21) or severe (n = 15)
dysplasia (tumor cellularity 60–80%). They reached the
same conclusion in all cases. All cases completed a ques-
tionnaire containing information on a family history of
cancer and the included cases had no known personal his-
tory of cancer. The KAM cohort consists of an ethnic
homogeneous group of Norwegian origin. The KAM study
is approved by the Regional Ethics Committee and The
Data Inspectorate.
Total RNA was purified from normal colonic mucosa and
lesions as recommended by the manufacturers using
NucleoSpin DNA II kit (Macherey Nagel). The tissue had
been snap frozen in liquid N2 before RNA purification.
RNA purification included a DNAse treatment. The cDNA
synthesis was performed on ca. 200 ng RNA in a final vol-BMC Cancer 2006, 6:208 http://www.biomedcentral.com/1471-2407/6/208
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ume of 10 μl using Gold RT-PCR kit (Applied Biosystems,
Nærum, Denmark).
Quantitative PCR was performed on ABI 7500 sequence
detection system (Applied Biosystems, Nærum, Den-
mark) in universal mastermix (Applied Biosystems,
Nærum, Denmark) using 100 nM Taqman probe and 200
nM primers for ERCC1 and for OGG1, 100 nM probe and
600 nM primers for RAI. ERCC1, OGG1 and RAI primers
and probes were obtained from TAG Copenhagen,
Copenhagen, Denmark. The OGG1 probe recognizes all
splice forms of OGG1. The expression was normalized to
18S rRNA. 18S primers and probes were commercially
available from Applied Biosystems, Nærum, Denmark.
The quantification of mRNA levels has been described
previously [22,34]. The probes and primers have been val-
idated, and the PCR was shown to be quantitative over a
range of 130-fold dilution for ERCC1 and OGG1 and over
a 32-fold range for RAI. mRNA measurements were
excluded if the 18S content was below the detection level
of the individual mRNA defined by the validation experi-
ments. ERCC1, OGG1, RAI mRNA and 18S levels were
quantified in triplicate in separate wells. The average
mRNA level of the specific mRNAs was then normalized
to the average 18S level. The average standard deviation
on triplicates was 15 %. The standard deviations on
repeated measurements of the same sample (the control)
in separate experiments were 34%, 21% and 25% for
ERCC1, OGG1 and RAI, respectively, indicating the day-
to-day variation of the assay. Independent PCR reactions
of the same samples yielded a correlation coefficient of
0.97. Negative controls (where the RNA was not con-
verted to cDNA) and positive controls were included in all
sets.
For comparison of different mRNA expression levels
between normal tissue and lesions in cases we used paired
t-test. When comparing expression levels in normal
colonic mucosa from all cases, and lesions in all the cases
separately, a one-way ANOVA test was used. P values <
0.05 were considered significant for all statistical tests. For
trend analysis of normal colonic mucosa in OGG1 and
RAI  we used logistic regression after dividing cases in
mild/moderate dysplasia (1), severe dysplasia (2) and
CRC (3). MiniTab Statistical Software, Release 13.1 Xtra
(Minitab Inc.) was used for statistical calculations.
Results
The distributions of age and gender are described in Table
1. Cases are divided into three groups according to diag-
nosed degree of dysplasia; adenomas (mild/moderate or
severe dysplasia) and carcinomas. mRNA expression in
normal colonic mucosa and all lesions for the three genes,
ERCC1, OGG1 and RAI are displayed separately in Figure
1 (A, B, C), and mean values are displayed in Table 2.
For all three genes, ERCC1, OGG1 and RAI, a comparison
of expression levels between normal colonic mucosa and
lesions in all cases combined (adenomas and CRC)
yielded significantly higher expression levels in lesions,
3.3-fold P = 0.005, 5.6-fold P < 3*10-5 and 7.7-fold P =
0.0005, respectively. When comparing expression levels
between normal colonic mucosa and lesions separately
for each case group (mild/moderate dysplasia, severe dys-
plasia and CRC), we detected significantly higher expres-
sion levels for ERCC1 and RAI in cases with severe degree
of dysplasia and for OGG1 we detected significantly
higher expression levels in cases with severe degrees of
dysplasia and CRC (Table 2).
When comparing expression levels of ERCC1 in lesions
only, we detected no difference between the adenoma and
CRC case groups, P = 0.836. This was also true for normal
tissue, P = 0.291, (Fig 1A).
The level of OGG1 expression when comparing lesions
did not differ between adenoma and CRC cases P = 0.34,
(Fig 1B), but for normal colonic mucosa the OGG1
expression in CRC patients was statistically significantly
lower than in normal colonic mucosa from adenoma
cases with mild/moderate dysplasia, P = 0.012, (Fig 1B). A
trend of lowered mRNA expression with increasing degree
of dysplasia was also observed in normal colonic mucosa,
P = 0.003.
The level of RAI expression when comparing lesions did
not differ between adenoma and CRC cases, P = 0.909,
(Fig 1C). The level of expression in normal colonic
mucosa was however significantly lower in CRC cases
compared to adenoma cases with mild/moderate dyspla-
sia, P = 0.043, (Fig 1C). A trend of lowered mRNA expres-
sion with increasing degree of dysplasia was also observed
in normal colonic mucosa, P = 0.011.
Discussion
In this study we have measured mRNA levels of ERCC1,
OGG1 and RAI in patients with colorectal adenomas and
carcinomas (normal colonic mucosa and lesions). We
have compared expression levels between corresponding
normal colonic mucosa and lesions in both adenoma and
CRC cases. In order to see if an increase in expression is an
early or late event in the adenoma-carcinoma sequence we
have also compared expression levels between case groups
in normal colonic mucosa and lesions separately.
ERCC1 expression was statistically significantly higher in
lesions than in the corresponding normal tissue when all
cases were combined. For OGG1  and  RAI, a similarBMC Cancer 2006, 6:208 http://www.biomedcentral.com/1471-2407/6/208
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increase in mRNA levels in lesions compared to the corre-
sponding normal colonic mucosa was detected. Previous
studies have shown that the mRNA levels of ERCC1 [11-
13,15,35] and OGG1 [10,14,27] correlate with the DNA-
repair capacity in various tissues. The increased mRNA
level detected in lesions in this study may therefore be
interpreted as enhanced DNA repair activity.
Low expression of DNA repair genes in lymphocytes have
previously been shown in patients with breast cancer,
lung cancer and cancer of the head and neck [4-7]. This
has been interpreted as low DNA repair gene expression is
a risk factor for cancer. For both OGG1 and RAI we found
that the expression was lower in normal colonic mucosa
from CRC patients than in normal colonic mucosa from
persons with mild/moderate dysplasia. This lowered
mRNA level can either be interpreted as a risk factor for
adenoma and CRC development but it can also be a con-
sequence of the same.
When comparing different lesions in the adenoma-carci-
noma sequence, we detected no significant difference in
expression. This was true for all three genes, ERCC1,
OGG1 and RAI. This may indicate that increased expres-
sion of DNA repair is an early event in the adenoma-carci-
noma sequence. The result for RAI may be an indication
that  RAI  and  ERCC1  are coordinated as they both are
located on chromosome 19q13.2. The NER gene XPD is
also located on chromosome 19q13.2 and a previous
study by Vogel et al concluded that ERCC1  and  XPD
mRNA quantities were highly correlated [13]. The RAI
mRNA is many-fold induced during apoptosis and the
induction is essential to apoptosis (Magdalena Laska et al,
manuscript in preparation). Increased RAI expression has
previously been observed in acute leukaemia cells [36].
We and others have found that RAI mRNA is also often
increased in cancer cells (Bergamaschi et al [30] and this
paper). We interpret this increase as an attempt on the
part of the cancer cells to activate the apoptotic pathway.
However, that attempt is presumably abortive as the can-
mRNA expression of ERCC1, OGG1 and RAI in lesions Figure 1
mRNA expression of ERCC1, OGG1 and RAI in lesions. 
mRNA levels were normalized to the 18S mRNA level. The 
classification of lesions are; M/M: adenoma with mild or mod-
erate dysplasia; S: adenomas with severe dysplasia; C: adeno-
carcinomas. Open squares designate the expression level in 
normal colonic mucosa while crossbars designate the expres-
sion in lesions. A: ERCC1, B: OGG1, C: RAI. * designate statis-
tically significant different mRNA levels in normal colonic 
mucosa compared with lesions in the same persons (p < 
0.05).













































































Table 1: Distribution of age and gender.
Cases
Adenomasa CRC
Mild/moderat dysplasia Severe dysplasia
(n = 21) (n = 15) (n = 9)
Menb 16 (76%) 13 (87%) 7 (78%)
Womenb 5 (24%) 2 (13%) 2 (22%)
Mean age +SDc 59.0 ± 3.1 58.4 ± 4.3 61.67 ± 9.1
a The adenomas are divided in groups according to diagnosed degree of dysplasia (mild/medium or severe).
b There is no significant difference in the number of males and females between the three case groups (χ2 test).
c There is no significant difference in age between the three case groups (Mann-Whitney test).BMC Cancer 2006, 6:208 http://www.biomedcentral.com/1471-2407/6/208
Page 5 of 7
(page number not for citation purposes)
cer cells continue to multiply. Possibly, the well-known
derangement of the intracellular control in cancer cells
may have destroyed other essential factors and/or the
downstream response.
Higher expression of DNA repair genes in lesions com-
pared with normal colonic mucosa may indicate chem-
oresistance. The difference in expression levels between
normal colonic mucosa and lesions for both ERCC1 and
OGG1 could mean that lesions in general have a higher
DNA repair capacity and therefore is less sensitive to DNA
damaging agents such as chemotherapy. Shirota et al
showed that CRC patients with low levels of intratumoral
mRNA ERCC1 expression had significantly better survival
than patients with high expression, when treated with 5-
FU and oxaliplatin as second- or third-line chemotherapy
[21].
Hereditary cancer predisposition syndromes have pro-
vided insight to the importance of DNA repair, but there
are only limited data on inter-individual variation in DNA
repair and susceptibility to sporadic cancer. Vogel et al
detected an inter-individual mRNA variation for ERCC1
and OGG1 that was 5–10 fold in healthy volunteers [22],
and a study by Paz-Elillzur et al concluded that low OGG1
activity was associated with an increased risk of lung can-
cer [37]. However, in the only prospective study of mRNA
levels of DNA repair genes and RAI, low expressions of
ERCC1, XPD or RAI were not associated with increased
risk of lung cancer [38]. In a study by Hansen et al [39] the
OGG1 Ser326Cys polymorphism, which has a reduced gly-
cosylase activity [40], was not associated with an
increased risk of colorectal adenomas or carcinomas.
Conclusion
In conclusion, mRNA levels of ERCC1 and OGG1 were
up-regulated in both colorectal adenomas and carcino-
mas compared to corresponding normal colonic mucosa,
indicating that increased expression of defense genes is an
early event in the progression of colorectal adenomas to
CRC. There are some issues that must be considered when
evaluating our findings. The number of cases is relatively
small, therefore there is a possibility that the reported
findings are due to chance. Larger prospective studies
would be required to clarify this issue.
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Table 2: Mean normalized ERCC1, OGG1 and RAI mRNA levels in normal colonic mucosa and lesions.
ERCC1 OGG1 RAI
Mean level × 1000a Mean level × 1000a Mean level × 1000a
Type of 
tissue
Normal Lesions Pb 95% CI Normal Lesions Pb 95% CI Normal Lesions Pb 95% CI
All cases 
combined




0.76 2.2 0.151 (-0.9 ; 3.5) 0.44 2.13 0.069 (-0.2 ; 3.6) 0.31 3.1 0.135 (-1.6 ; 6.6)
Severe 0.39 1.5 0.027 (0.15 ; 2.1) 0.35 1.68 0.004 (0.5 ; 2.2) 0.28 1.85 0.0014 (0.4 ; 1.5)
CRC 0.16 1.5 0.109 (-0.4 ; 3.1) 0.24 1.83 0.034 (0.2 ; 3.0) 0.18 1.46 0.09 (-0.3 ; 2.8)
a) Since ERCC1, OGG1 and RAI expression is expressed as a ratio, normalized, to 18S rRNA expression, it is unit-less.
b) Comparison of the expression levels in lesions and normal colonic mucosa from the same persons.
c) The adenomas are divided in groups according to mild/moderate dysplasia or severe dysplasia.BMC Cancer 2006, 6:208 http://www.biomedcentral.com/1471-2407/6/208
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